Literature DB >> 1309735

Purified I kappa B-beta is inactivated upon dephosphorylation.

E Link1, L D Kerr, R Schreck, U Zabel, I Verma, P A Baeuerle.   

Abstract

In uninduced cells, the NF-kappa B transcription factor resides in the cytoplasm in complex with an inhibitory protein, I kappa B. I kappa B is a specific inhibitor of DNA binding and apparently prevents nuclear uptake of NF-kappa B. Stimulation of cells, for instance with the cytokine tumor necrosis factor, releases I kappa B and allows nuclear translocation and DNA binding of NF-kappa B to regulatory DNA sequences in many genes. We recently reported on the purification of a major form of I kappa B, referred to as I kappa B-alpha, with a molecular size of 37 kDa. Here, we purified and characterized I kappa B-beta, a chromatographically distinct second form of I kappa B. I kappa B-beta has a size of 43 kDa and, as I kappa B-alpha, an acidic isoelectric point between 4.8 and 5.0. Both forms of I kappa B were inactivated by a treatment with protein kinases A and C in vitro. In contrast to I kappa B-alpha, I kappa B-beta lost its inhibiting activity upon a treatment with phosphatase. Phosphatase treatment also released active NF-kappa B from its inactive complex with I kappa B-beta suggesting that the activation of NF-kappa B in intact cells might not only rely on phosphate transfer onto I kappa B but also on phosphate removal from one form of I kappa B.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1309735

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  36 in total

Review 1.  One path to cell death in the nervous system.

Authors:  J Glasgow; R Perez-Polo
Journal:  Neurochem Res       Date:  2000-10       Impact factor: 3.996

2.  Effect of cyclic GMP-dependent vasodilators on the expression of inducible nitric oxide synthase in vascular smooth muscle cells: role of cyclic AMP.

Authors:  M Boese; R Busse; A Mülsch; V Schini-Kerth
Journal:  Br J Pharmacol       Date:  1996-10       Impact factor: 8.739

3.  Role of unphosphorylated, newly synthesized I kappa B beta in persistent activation of NF-kappa B.

Authors:  H Suyang; R Phillips; I Douglas; S Ghosh
Journal:  Mol Cell Biol       Date:  1996-10       Impact factor: 4.272

4.  Distinct functional properties of IkappaB alpha and IkappaB beta.

Authors:  K Tran; M Merika; D Thanos
Journal:  Mol Cell Biol       Date:  1997-09       Impact factor: 4.272

5.  Alternative splicing variants of IkappaB beta establish differential NF-kappaB signal responsiveness in human cells.

Authors:  F Hirano; M Chung; H Tanaka; N Maruyama; I Makino; D D Moore; C Scheidereit
Journal:  Mol Cell Biol       Date:  1998-05       Impact factor: 4.272

6.  Tax induces nuclear translocation of NF-kappa B through dissociation of cytoplasmic complexes containing p105 or p100 but does not induce degradation of I kappa B alpha/MAD3.

Authors:  E Muñoz; G Courtois; P Veschambre; P Jalinot; A Israël
Journal:  J Virol       Date:  1994-12       Impact factor: 5.103

7.  Alternate RNA splicing of murine nfkb1 generates a nuclear isoform of the p50 precursor NF-kappa B1 that can function as a transactivator of NF-kappa B-regulated transcription.

Authors:  R J Grumont; J Fecondo; S Gerondakis
Journal:  Mol Cell Biol       Date:  1994-12       Impact factor: 4.272

8.  CpG-ODN-mediated TLR9 innate immune signalling and calcium dyshomeostasis converge on the NFκB inhibitory protein IκBβ to drive IL1α and IL1β expression.

Authors:  Robyn De Dios; Leanna Nguyen; Sankar Ghosh; Sarah McKenna; Clyde J Wright
Journal:  Immunology       Date:  2020-03-18       Impact factor: 7.397

9.  Paclitaxel (Taxol)-induced NF-kappaB translocation in murine macrophages.

Authors:  P Y Perera; N Qureshi; S N Vogel
Journal:  Infect Immun       Date:  1996-03       Impact factor: 3.441

10.  Human T-cell lymphotropic virus type 1 Tax1 activation of NF-kappa B: involvement of the protein kinase C pathway.

Authors:  P F Lindholm; M Tamami; J Makowski; J N Brady
Journal:  J Virol       Date:  1996-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.